Author: Zhenhua Zeng; Tong Sha; Yuan Zhang; Feng Wu; Hongbin Hu; Haijun Li; Jiafa Han; Wenhong Song; Qiaobing Huang; Zhongqing Chen
                    Title: Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study  Document date: 2020_4_11
                    ID: lujxql3a_34
                    
                    Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.06.20054825 doi: medRxiv preprint to that of ACE. ACE2 can hydrolyze angiotensin I (Ang I) to produce angiotensin (1-7) peptides, thereby generating vasodilation and lowering blood pressure. ACEI/ARB drugs may increase the protein concentration of ACE2 in rat plasma, mRNA level of ACE2, and even the activity of ACE2 in cardiac tissue 14 ......
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.06.20054825 doi: medRxiv preprint to that of ACE. ACE2 can hydrolyze angiotensin I (Ang I) to produce angiotensin (1-7) peptides, thereby generating vasodilation and lowering blood pressure. ACEI/ARB drugs may increase the protein concentration of ACE2 in rat plasma, mRNA level of ACE2, and even the activity of ACE2 in cardiac tissue 14 . Thus, it is possible that those hypertensive patients who had been taking ACEI/ARB might have an increased level of mRNA and protein expression of ACE2 in the lungs, making them more vulnerable for SARS-COV-2 entry, as well as for development of severe COVID-19 pneumonia. These findings are worth investigating further.
 
  Search related documents: 
                                Co phrase  search for related documents- ARB drug and SARS entry: 1
  - blood pressure and cardiac tissue: 1, 2, 3, 4, 5, 6
  - blood pressure and hypertensive patient: 1, 2, 3, 4, 5, 6
  - blood pressure and increase level: 1, 2, 3, 4, 5, 6, 7, 8, 9
  - blood pressure and mRNA level: 1
  - blood pressure and protein concentration: 1, 2, 3, 4, 5
  - blood pressure and protein expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
  - blood pressure and SARS entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
  - blood pressure and severe pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
  - blood pressure and severe pneumonia development: 1
  - blood pressure lower and protein expression: 1
  - blood pressure lower and severe pneumonia: 1, 2
  - cardiac tissue and mRNA level: 1
  - cardiac tissue and protein expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
  - cardiac tissue and SARS entry: 1, 2, 3, 4, 5, 6, 7
  - hypertensive patient and severe pneumonia: 1, 2, 3, 4, 5
  - increase level and mRNA increase level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
  - increase level and mRNA level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
  - increase level and protein concentration: 1
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date